Aytu Biopharma (AYTU) Total Current Liabilities (2011 - 2026)

Aytu Biopharma (AYTU) has 16 years of Total Current Liabilities data on file, last reported at $60.0 million in Q1 2026.

• Total Current Liabilities for Q1 2026 came in at $60.0 million, down 15.18% year-over-year; the trailing twelve-month figure through Mar 2026 was $60.0 million (down 15.18% YoY), and the FY2025 annual result was $63.1 million, up 1.34% from the prior year.
• Total Current Liabilities retreated to $60.0 million in Q1 2026 per AYTU's latest filing, from $65.6 million in the prior quarter.
• Over five years, Total Current Liabilities peaked at $85.4 million in Q1 2023 and troughed at $60.0 million in Q1 2026.
• A 5-year average of $68.6 million and a median of $65.6 million in 2025 frame the typical range for Total Current Liabilities.
• The sharpest annual moves came in 2022 and 2025: Total Current Liabilities plunged 41.12% in 2022, then rose 7.74% in 2025.
• A 5-year view of Total Current Liabilities shows it stood at $67.1 million in 2022, then retreated by 4.41% to $64.2 million in 2023, then slipped by 0.22% to $64.0 million in 2024, then increased by 2.37% to $65.6 million in 2025, then declined by 8.53% to $60.0 million in 2026.
• Business Quant data shows AYTU's Total Current Liabilities at $60.0 million in Q1 2026, $65.6 million in Q4 2025, and $66.0 million in Q3 2025.